LANSING, Mich., March 25, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company"), the leading developer of advanced spider silk based fibers, announced today that Dr. Malcolm Fraser, PhD, an influential member of the Company's scientific advisory board, is in India meeting with scientists, government officials and industry. The Company's CEO and Founder, Kim Thompson, is also traveling and is currently in another country meeting with government officials and businessmen to discus and explore production and processing opportunities for Monster Silk™ and other recombinant spider silks.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com
Source:Kraig Biocraft Laboratories, Inc